Spiritus Bioscience is a biotechnology startup dedicated to enhancing drug delivery methods for pressing mental health issues. The company's slogan encapsulates its mission to revamp existing strategies for drug delivery. With a team of skilled scientists and specialists, Spiritus aims to develop patentable drug delivery products to address unmet needs in mental health and neuropsychiatric disorders.
Currently, the company is on the verge of introducing its proprietary, patented, and ground-breaking method of delivery in Phase I and II trials. Notably, its unique clinical trial design allows for expedited data collection with reduced time and costs, setting it apart from conventional approaches.
Spiritus Bioscience's last investment, a Venture Round, was secured on 01 August 2023 from Mystic Ventures. This investment will likely play a crucial role in advancing the startup's innovative drug delivery solutions for mental health treatments.
-logo.jpg "Emyria (ASX:EMD)"){kind=logo}
